SuperworthAimei Health Technology EPS AFJK
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $0.09
- Latest quarter, Q2 FY26
- −$0.03
- −143% on a year earlier
- Fiscal year 2025
- $0.21
- −52% on the year before
Aimei Health Technology's earnings per share was $0.09 over the twelve months to Jun 30, 2026, down 77% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.03, down 143% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.21 | −52% |
| FY2024 | $0.44 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.03 | −143% | $0.09 | |
| Q1 FY26 | $0.01 | −67% | $0.19 | |
| Q4 FY25 | $0.05 | −76% | $0.21 | |
| Q3 FY25 | $0.06 | −25% | $0.37 | |
| Q2 FY25 | $0.07 | +0% | $0.39 | |
| Q1 FY25 | $0.03 | −63% | $0.39 | |
| Q4 FY24 | $0.21 | n/a | $0.44 | |
| Q3 FY24 | $0.08 | n/a | n/a | |
| Q2 FY24 | $0.07 | n/a | n/a | |
| Q1 FY24 | $0.08 | n/a | n/a |
Against its peers
Companies in Financial Services nearest Aimei Health Technology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AFJKAimei Health Technology | $0.09 | |
| MBBCMarathon Bancorp | $0.67 | +6600% a year |
| GROWU S Global Investors | $0.24 | |
| TCBSTexas Community Bancshares | $1.21 | +51% a year |
| ATCHAtlasClear | $0.01 | |
| RSSSResearch Solutions | $0.09 | +200% a year |
| CLSTCatalyst Bancorp | $0.54 | −5% a year |
| VIPVulcan Infrastructure & Power | $0.07 | |
| UBCPUnited Bancorp | $1.38 | +9% a year |
| BCGBinah Capital | $0.16 | |
| HNNAHennessy Advisors | $1.05 | −16% a year |
| Peer median | $0.39 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aimei Health Technology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.